Praxis Precision Medicines shares are higher in Friday trading as investors react to a key regulatory step: the FDA has accepted the company’s NDA for ulixacaltamide HCl to treat essential tremor in adults. FDA filing acceptance is typically viewed as a major de-risking milestone because it confirms the application is sufficiently complete to enter formal review. (investing.com)

The acceptance lands just ahead of the American Academy of Neurology Annual Meeting in Chicago (April 19–22, 2026), where Praxis has said it will deliver multiple oral presentations and posters on ulixacaltamide. With the program already positioned as a potential first specifically developed therapy for essential tremor, investors are treating the near-term conference window as another catalyst for sentiment and visibility. (ir.praxismedicines.com)

Praxis has been building toward commercialization, highlighting that it submitted NDAs for both ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A developmental and epileptic encephalopathies), and has been scaling pre-launch activities. The company also reported a substantial cash position at year-end 2025 and noted additional financing proceeds in January 2026 intended to fund operations into 2028, reducing near-term financing overhang as regulatory timelines progress. (ir.praxismedicines.com)